Obinutuzumab for PLA2R antibodies in membranous nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is testing a drug called obinutuzumab to see if it can lower PLA2R antibodies in people with membranous nephropathy (a kidney disease). The goal is to reduce protein leakage in urine and improve kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with primary membranous nephropathy (PMN) confirmed by a kidney biopsy or a blood test for PLA2R antibodies.
- Your PLA2R antibody level is above 80 RU/ml.
- You have significant protein in your urine (3.5 grams or more per day) despite at least 6 months of blood pressure medication.
- Your kidney function (eGFR) is 30 ml/min or higher.
- You have not used rituximab in the last 12 months, or other immunosuppressive drugs in the last 2-6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
This trial tests a medication called obinutuzumab for people with lupus-related kidney disease, specifically a type called pure membranous nephropathy. The goal is to see if it helps reduce protein leaking into the urine and improves kidney health.
This trial tests whether obinutuzumab, a targeted therapy that quiets certain immune cells, can reduce kidney damage in people with fibrillary glomerulonephritis. If you have this rare kidney condition and significant protein in your urine, this study may offer a new treatment option.
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
This trial tests a new drug called obinutuzumab for adults whose nephrotic syndrome (a kidney disease causing swelling and protein in urine) has relapsed after stopping rituximab. It aims to see if obinutuzumab can help prevent future relapses.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
Hear when a new Membranous Nephropathy - PLA2R Induced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.